Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond established risk scores, their comparative impact among different European regions and their role in the drive towards individualized medicine remains uncertain. Within BiomarCaRE we use our unique resources and an established infrastructure to collaboratively assess the predictive value biomarkers in an interdisciplinary approach. A large panel of biomarkers including established protein-based markers such as NTproBNP and troponin as well as emerging biomarkers such as Omics markers is assessed to improved disease prediction among different European populations. Collaborations with world-class clinical trial investigators add data on the interaction of the BiomarCaRE panel with risk-lowering medication, lifestyle changes and opens the way for individualized approaches. Moreover, cost-effectiveness analyses adds to the clinical evaluation of the BiomarCaRE panel. Thereby, BiomarCaRE is unique in terms of its dimension, targeting of novel biomarkers, and the evaluation of the impact of a multiple biomarker score in large prospective population cohorts across different European regions.
See also: Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, Ruijter HD, Schnabel RB, Kee F, Salomaa V, Siebert U, Thorand B, Ziegler A, Breek H, Pasterkamp G, Kuulasmaa K, Koenig W, Blankenberg S (2014): BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries. Eur J Epidemiol, 29(10):777-90.